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STRATEGIES TO COMBAT DRUG-RESISTANT TUBERCULOSIS:
INHALABLE MICROPARTICLES FORMULATED WITH ANTI-TUBERCULAR
ANTIBIOTICS AND EFFLUX PUMP INHIBITORS
By
ELLIOTT KINOSHITA MILLER
B.S., BIOLOGY, UNIVERSITY OF NEW MEXICO, 2014
MASTERS OF SCIENCES
PHARMACEUTICAL SCIENCES
ABSTRACT
Mycobacterium tuberculosis (Mtb) is an intracellular pathogen which can
remain dormant within the human body for years (latent tuberculosis), and once
active requires extensive multidrug therapies for treatment. Long-term antibiotic(s)
exposure have led to the emergence of multidrug-resistant (MDR) and extensively
drug-resistant (XDR) strains which require novel treatment approaches to combat
Mtb resistance. Mtb may also utilize efflux pumps to expel antibiotics and promote
bacterial survival, potentially mediating drug tolerance, which has been
hypothesized to contribute to antibiotic resistance. Efflux pump inhibitors (EPIs)
such as verapamil (VER) may potentiate effects of first-line anti-tubercular drugs
(ATDs) such as rifampicin (RIF).
The goal of this project is to formulate and characterize a microparticulate
inhalational delivery system consisting of a sustained released (SR) EPI and
immediate release (IR) RIF. This formulation can be beneficial by (1) allowing for
higher bactericidal concentrations at the site of infection when compared to
systemic delivery, (2) improved bactericidal killing with efflux pump inhibition,
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potentially leading to shorter treatment durations, and (3) combating mechanisms
that can contribute to the selection of drug-resistant Mtb.
We hypothesize that formulating the VER (the model EPI) into a SR system
through the integration of the polymer Eudragit E PO (EPO) in combination with IR
RIF through the integration of mannitol and leucine (ML) will potentiate the antitubercular activity of our formulation against Mtb, compared to traditional systemic
delivery with no EPI. The slow release of VER will potentially prolong the inhibition
of efflux pumps; further, concentration-dependent RIF will be immediately released
thus allowing high intra-bacterial concentrations of the ATD. This novel formulation
exploits properties of the EPO polymer, which is soluble at pH below 5.0, such that
once the microparticles are taken up by the alveolar macrophage (in which Mtb
resides), the entire payload will be immediately released. Such a formulation could
improve the sterilizing activity of RIF which could decrease the total amount of ATD
required and potentially shorten treatment durations.
Microparticles (MPs) with VER and RIF were formulated using a Buchi 290
laboratory scale mini-spray dryer in aqueous solvents. Briefly, MPs of IR-RIF, IRVER, and SR-VER were prepared. These powders were further mixed
homogenously to produce the formulations of interest (IR-RIF/IR-VER and IRRIF/SR-VER). MPs were characterized for volumetric and aerodynamic particle
sizing using Malvern Mastersizer 3000 with an attached dry powder disperser
(Aerosizer), and a Next Generation Impactor (NGI, Copley Scientific, UK),
respectively. For all powders (individual and mixed), we were able to achieve a
volumetric diameter (D-50) in the size range of 1.77 - 2.63 µm. Further, we were
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able to achieve a mass median aerodynamic diameter (MMAD) in the size range
2.45 – 4.95 µm for the above powders. With regard to the mixed powders, the IRRIF/IR-VER formulation achieved a RIF:VER ratio of 2.33:1 (wt/wt). The IRRIF/SR-VER formulation achieved a RIF:VER ratio of 2.58:1 (wt/wt). For the IRRIF/IR-VER mixed powder both drugs showed approximately 70% drug release at
4 hours. With the IR-RIF/SR-VER mixed powder, however, the RIF component
achieved only 60% drug release at 4 hours where the VER component was able
to achieve approximately 80% release. For both formulations a release of nearly
100% was achieved for both the EPI and ATD.
The in vitro cytotoxicity of the IR-RIF/IR-VER formulation at 1 milligram (of
dry powder) per milliliter after 24 hours of exposure led to only 14.47% ± 0.29%
THP-1 cellular viability. Lower concentrations achieved higher cell viability, with
approximately 45% for the 500 micrograms per milliliter, and over 99% cellular
viability at concentrations of 250 micrograms per milliliter or less. IR-RIF/SR-VER
formulation was around 30% cell viability for all concentrations evaluated. The in
vitro bacterial (Mycobacterium smegmatis) killing of the IR-RIF/IR-VER formulation
achieved higher killing of the mycobacterium at lower drug concentrations when
compared to that of the IR-RIF/SR-VER formulation.
The above data demonstrated the feasibility of spray drying to develop an
inhalable dry powder formulation with properties suitable for delivery to the deep
lung (based on aerodynamic size), macrophage uptake (based on volumetric size),
toxicity studies (in THP-1 cells) and mycobacterial killing (using M. smegmatis as
a surrogate mycobacteria). The data also suggest that our IR formulation was less
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toxic to macrophages and more effective in mycobacterial killing at lower
concentrations than our SR formulation. The drug release studies, however,
provided inconclusive results for both the formulations.
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CHAPTER 1: INTRODUCTION
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Introduction
Tuberculosis (TB) is an airborne pathogen that infects ~10.4 million people
and results in 1.8 million deaths annually; this makes TB the leading cause of death
from a single infectious agent, ranking above HIV/AIDS (WHO, 2017). TB can
remain dormant within the human body for years without showing any symptoms;
however once active, treatment requires complex and extensive multidrug
therapies administered over 6 to 9 months (CDC, 2014b). This long-drawn and
demanding treatment has led to the emergence of drug-resistant Mycobacterium
tuberculosis (Mtb); future therapies may require a different approach to combat the
further selection and advancement of these dangerous multidrug-resistant (MDR)
and extensively drug-resistant (XDR) strains of TB (CDC, 2014a). Identifying the
mechanisms by which these organisms acquire resistance is critical to combat
drug resistance. This will allow first-line therapies to remain viable, thus extending
the longevity of the limited antibiotics that provide favorable outcomes in TB
treatment. One such mechanism has been identified that Mtb employs to avoid
death. Mtb utilizes efflux pumps to remove intracellular drug and thus promote
bacterial survival, mediating variable levels of drug tolerance ((Gupta et al., 2013),
(Adams et al., 2011)). Researchers have successfully repurposed drugs such as
verapamil (VER) and thioridazine (TRZ) and have shown them to be effective efflux
pump inhibitors (EPIs), thus combating drug tolerance mechanisms of TB as well
as potentiate the effects of first-line treatment options such as rifampin (RIF) and
isoniazid (INH) ((Gupta et al., 2013), (Vibe et al., 2016)). Various ways of
incorporating these combination drugs (EPIs and anti-TB drugs) into a single
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formulation and determining the best route of administration and optimal drug
release profile for each antibiotic remains to be resolved.
Tuberculosis Pathogenesis
TB is an infectious disease most often affecting the lungs. TB’s causative
pathogen is the bacterium Mtb. This opportunistic bacterium invades the host via
airborne droplet nuclei, however other methods of host invasion occur via the
gastrointestinal tract from ingestion or via cutaneous routes in compromised skin
(Nicas, Nazaroff, & Hubbard, 2005). The primary source of infection, droplet nuclei,
are respired from one infected host after a cough or sneeze and can remain
suspended in the air for hours (Nicas et al., 2005).
After inhalation of droplet nuclei has been achieved in a susceptible host,
bacteria are deposited in the lung, where the Mtb will be phagocytosed by alveolar
macrophages (Philips & Ernst, 2011). Once inside the macrophage, Mtb employs
strategies

to

prevent

bacterial death

by

preventing

formation

of

the

phagolysosome, which gives the bacteria an environment to multiply and a means
to manifest disease outside of the lungs (Marino et al., 2014). The TB infection can
potentially migrate out of the lungs via the lymphatic system and will most often
disseminate to the liver, spleen, kidney, bone and brain (Philips & Ernst, 2011),
(O’Garra et al., 2013). Within 4 weeks of infection taking residence within
macrophages, a cell-mediated immunity is initiated which recruits cytotoxic T-cells
to kill the Mtb-infected macrophages. This cascade of events triggers a delayedtype hypersensitivity (DTH) response, promoting invasion of phagocytic cells
which release fluid and digestive enzymes to the sites of infection. This DTH
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response causes inflammation which is the primary source of damage to the lungs
and other tissues that occurs in TB infection (Price & Muttil, 2016), (Ehrt &
Schnappinger, 2009).
Another fate of Mtb-infected macrophages is isolation within granulomas,
which is generally a cluster of macrophages, lymphocytes, fibroblasts and giant
cells. These granulomatous formations will generally create a hostile, anaerobic
environment for the Mtb, which restricts the bacteria’s ability to multiply, slowly
decreasing the bacterial burden and allowing the granuloma to form fibrous caps

Figure.1.1. The life cycle of Mtb (from Russell, D. G., Barry, C. E., & Flynn, J. L. (2010). Tuberculosis: What We
Don’t Know, Science. 328, 852–857. Reprinted with permission from AAAS.)
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(Marino et al., 2014), (Russell, Barry, & Flynn, 2010). Figure 1.1 shows the
potential pathway that a bacterium from an inhaled droplet can manifest inside a
granuloma which could ultimately result in the release of Mtb to cause active
infection.
Primary Tuberculosis Treatment
Although TB may require treatment durations of at least 6 months, it is a
treatable infection for many inflicted with this disease. There are many ATDs
approved for the treatment of TB and are shown in Table 1.1. However, other
agents which are currently not approved are used when preferred treatment fails
(Table 1.1). First line therapy for the treatment of susceptible Mtb consists of
isoniazid (INH), rifamycins such as rifampicin or rifampin (RIF), pyrazinamide
(PZA), and ethambutol (EMB). For the first 2 months of treatment, the Mtb-infected
patient will take all 4 of these ATDs together which is known as the initial treatment
phase. For the remaining 4 months of treatment, the patient will receive only RIF
and INH in combination in what is known as the continuation phase (CDC, 2014b).
Treatment of pulmonary, susceptible TB may seem to be a relatively straight
forward regimen, however aspects of the disease greatly complicate outcomes
such as the emergence of variably resistant Mtb, access to healthcare, a patient’s
willingness to complete the lengthy and rigorous treatment, and the marked side
effect profile of these medications (Table 1.1). Various treatment modalities,
including newer approved ATDs, are available for the treatment of these complex
infections; yet one of the goals of current TB therapy is to extend the longevity of
first-line ATDs. Understanding the mechanisms of tolerance and resistance is key
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to achieving this goal. Recent strategies of Mtb treatment have been targeted at
these aforementioned mechanisms, and will be discussed further in the coming
sections.

Table 1.1. Anti-Tubercular Drug Chart: Routes of Administration, Side Effects, and Special Considerations
Table adapted from Uptodate, IDSA, and Sanford Guidelines
* Dosing based on most frequent dosing strategies. Other dosing strategies may be available for each
individual agent

First-Line Anti-Tubercular Agents
Agent:
Mechanism of Action:

Dosing
Strategy*:

Isoniazid

Inhibits mycolic acid
synthesis

Daily

Rifampin

Inhibits transcription

Daily

Rifabutin

Inhibits transcription

Daily

Rifapentine

Inhibits transcription

Once
Weekly

Pyrazinamide

Converted to pyrazinoic
acid; acidifies Mtb
environment

Daily
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Common and/or Serious
Adverse Effects and Special
Considerations:
Hepatotoxicity, neurologic
reactions (pyridoxine can
prevent neurologic side
effects), monoamine oxidase
inhibitor-like activity (special
care with food high in
tyramine)
Red-orange discoloration of
body fluids, hepatitis,
cutaneous vasculitis, red cell
aplasia, leukopenia,
agranulocytosis,
thrombocytopenia, P-gp and
CYP3A inducer (many drug
interactions)
Red-orange discoloration of
body fluids, hematologic and
hepatotoxic effects similar to
rifampin, uveitis, UGT1A1
and CYP3A inducer (many
drug interactions)
Red-orange discoloration of
body fluids, GI toxicity,
hepatotoxicity,
hyperuricemia, LFT
elevations, CYP system
inducer, do not use in patients
with HIV
Hepatotoxicity, GI toxicity,
cutaneous hypersensitivity,
thrombocytopenia, anemia

Ethambutol

Inhibits arabinosyl
transferase; impairs
mycobacterial cell wall
synthesis

Daily

Second-Line Anti-Tubercular Agents:
Fluoroquinolones
Levofloxacin Inhibits DNA Gyrase
Daily
and DNA
Topoisomerase II;
prevents supercoiling
Moxifloxacin Inhibits DNA Gyrase
Daily
and DNA
Topoisomerase II;
prevents supercoiling
Injectable Agents
Amikacin
Binds 30S ribosomal
Daily
subunit; inhibits protein
synthesis
Kanamycin
Binds 30S ribosomal
Daily
subunit; inhibits protein
synthesis
Capreomycin Inhibition of protein
Daily
synthesis
Streptomycin

Ethionamide

Cycloserine

Linezolid

Optic neuropathy,
neutropenia,
thrombocytopenia, GI
toxicity, hepatotoxicity, CNS
toxicity, cutaneous
hypersensitivity
GI toxicity, CNS toxicity,
rash, glycemic changes,
tendonitis/tendon rupture, QT
prolongation
GI toxicity, CNS toxicity,
rash, glycemic changes,
tendonitis/tendon rupture, QT
prolongation, hepatotoxicity
Ototoxicity, nephrotoxicity,
electrolyte abnormalities, IM
injection site pain
Ototoxicity, nephrotoxicity,
electrolyte abnormalities

Ototoxicity, nephrotoxicity,
electrolyte abnormalities, IM
injection site pain
Binds 30S ribosomal
Daily
Ototoxicity, nephrotoxicity,
subunit; inhibits protein
electrolyte abnormalities, IM
synthesis
injection site pain
Additional Core Second-Line Agents
Inhibits peptide synthesis Twice Daily GI toxicity (premedicate with
antiemetics), hepatotoxicity,
metallic taste, neurotoxicity
(pyridoxine can help prevent
neurologic side effects),
hypothyroidism
Inhibits bacterial cell
Twice Daily CNS toxicity, peripheral
wall synthesis
neuropathy (pyridoxine can
help prevent neurologic side
effects), serious cutaneous
hypersensitivity
Binds 50S ribosomal
Daily
GI toxicity, neuropathy
subunit; inhibits bacterial
(pyridoxine can help prevent
protein synthesis
neurologic side effects),
myelosuppression
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Clofazimine

Exact mechanism
unknown

Daily

Add-On Agents
High-Dose
See Isoniazid above
Three Times
Isoniazid
Weekly
Bedaquiline
Inhibits mycobacterial
Daily
proton transfer chain;
interrupts ATP
generation
Delamanid
Inhibits mycolic acid
Twice Daily
synthesis
ParaInhibits folate synthesis
Three Times
aminosalicylic
Daily
acid
ImipenemInhibits transpeptidation Twice Daily
cilastatin
of peptidoglycan;
inhibits bacterial cell
wall synthesis
Meropenem
Inhibits transpeptidation Three Times
of peptidoglycan;
Daily
inhibits bacterial cell
wall synthesis
AmoxicillinInhibits transpeptidation Three Times
clavulanate
of peptidoglycan;
Daily
inhibits bacterial cell
wall synthesis
Thioacetazone Inhibits mycolic acid
Daily
synthesis

Red discoloration of body
fluids, GI toxicity,
photosensitivity, requires
application to the US FDA
See Isoniazid above
QT prolongation, hepatitis,
GI toxicity
QT prolongation, GI toxicity
GI toxicity, hepatotoxicity,
hypothyroidism
GI toxicity, seizures

GI toxicity, seizures

GI toxicity

GI toxicity,
myelosuppression, hepatitis,
peripheral neuropathy, do not
use in patients with HIV

Resistance Mechanisms and Strategies of Treatment
Resistance in Mtb is most often defined as a chromosomal change which
emerges only after repeated exposure to ATDs, suboptimal prescription access,
or poor patient adherence (Zhang & Yew, 2009). In particular, multi-drug resistant
TB (MDR-TB), which is defined as Mtb which is resistant to INH and RIF, and
extensively drug-resistant TB (XDR-TB), which is defined as Mtb which is resistant
to INH and RIF plus any fluoroquinolone and at least one injectable agent (Table
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1.1), have been of concern regarding medication changes to first-line treatments
and negatively impacting therapeutic outcomes (CDC, 2014a). When it has been
determined that a patient is infected with resistant TB, the course of treatment as
well as the effective agents used in the course of treatment are drastically affected.
This new ATD regimen will, however, consist of first and second-line agents based
on multiple factors (Table 1.1) (CDC, 2014b).
The mechanisms of resistance for these antibiotics has been well studied,
and exact gene mutations have been identified for the drugs which are most often
implemented in drug resistance (Table 1.2). Understanding these precise
mutations and the underlying physiological effect these mutation have allowed TB
research efforts to create medications specifically for MDR and XDR TB, such as
bedaquiline and delamanid (Koch, Mizrahi, & Warner, 2014), (Costa-Gouveia,
Aínsa, Brodin, & Lucía, 2017). Even with these advances to combat resistant TB,
Mtb has been able to utilize other mechanisms, such as efflux pump
overexpression, to gain resistance against these newer agents (Gupta et al.,
2014). This emphasizes the importance of understanding and inhibiting these
mechanisms in order to potentiate the use of first line ATDs as well as decrease
resistance against the newer agents specifically designed to combat resistant Mtb.
Table 1.2. Mechanism of drug resistance in Mtb-active agents. (Adapted from Zhang & Yew, 2009)

Mechanism of Drug Resistance in Mtb
Drug
INH
RIF

Gene
Gene function
involved
katG
Catalase-peroxidase
inhA
Enoyl ACP reductase
rpoB

b subunit of RNA
polymerase
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Role of Gene
Pro-drug
conversion
Drug Target
Drug Target

Mechanism of
Action
Inhibits
mycolic acid
synthesis
Inhibits RNA
synthesis

PZA

pncA

Nicotinamidease/
pyrazinamidease

Pro-drug
conversion

EMB

embB

Arabinosyl
transferase

Drug Target

Streptomycin

rpsL
rrs
gidB

Drug Target
Drug Target
Drug Target

Amikacin/
kanamycin
Capreomycin

rrs

S12 ribosomal
protein
16S rRNA
rRNA
methyltransferase
16S rRNA

N/A

Quinolones

gyrA
gyrB

Ethionamide

etaA/
ethA
inhA

2’-Omethyltransferase
DNA gyrase subunit
A
DNA gyrase subunit
B
Flavin
monooxygenase

tlyA

ParathyA
aminosalicylic
acid

Drug Target

Depletes
membrane
energy
Inhibits
arabinogalacta
n synthesis
Inhibits protein
synthesis

Inhibits protein
synthesis
N/A

Drug Target

Inhibits DNA
gyrase

Pro-drug
conversion

Inhibition of
mycolic acid
synthesis

Enoyl ACP reductase Drug Target
Thymidylate synthase Drug Activation
(?)

Inhibits folic
acid/ iron
metabolism (?)

Tolerance Mechanisms: Efflux Pumps
Resistance, however, is preceded by changes within the Mtb physiology
which does not require mutated gene expression; rather some changes which may
result in overexpression. This phenomenon is known as tolerance and fully
understanding these mechanisms provides additional methods of combating the
selection for resistant Mtb. One mechanism of tolerance in Mtb is overexpression
of efflux pumps which results from various insults to the Mtb environment, such as
macrophage phagocytosis or ATD exposure (Adams et al., 2011), (Gupta et al.,
2013).
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Efflux pumps are transmembrane proteins which are found in almost every
bacterial species (Sun, Deng, & Yan, 2014). These highly ubiquitous proteins can
be categorized into multiple superfamilies based on structural morphology,
substrate preference, and the source of energy used to facilitate efflux (Pule et al.,
2016). These include the ATP-binding cassette (ABC), the major facilitator
superfamily (MFS), the small multidrug resistance (SMR), and the resistancenodulation-cell division (RND). Figure 1.2 depicts the classes of the
aforementioned efflux pumps as well as substrate preference and the source of
energy to facilitate efflux.

Figure 1.2. Efflux pumps, efflux pump drug targets and efflux pump inhibitors. (From Pule, C. M., Sampson,
S. L., Warren, R. M., Black, P. A., van Helden, P. D., Victor, T. C., & Louw, G. E. (2016). Efflux pump
inhibitors: Targeting mycobacterial efflux systems to enhance TB therapy. Journal of Antimicrobial
Chemotherapy, 71(1), 17–26, by permission of Oxford University Press)
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Efflux Pump Inhibitors (EPIs)
Given the limited number of ATDs available, methods of restoring Mtb
susceptibility to first and second-line agents is crucial given the emergence of MDR
and XDR-TB (Pule et al., 2016). Efflux pump inhibition can partially restore
susceptibility of a select number of ATDs, extending the longevity of the few agents
approved for the use of Mtb infections. Some of the efflux pump inhibitors (EPIs)
of interest are repurposed drugs which are already approved for separate
indications, however have demonstrated great promise in terms of add-on
treatment to some Mtb treatment regimens. As table 1.3 illustrates, these
medications have the drawback of marked side effects as well as dosing strategies
that can require a patient to take these medications multiple times a day, however,
have much promise in terms of restoring susceptibility in tolerant and resistant Mtb
infections.
Table 1.3. Repurposed drugs for efflux pump inhibition Repurposed drugs for efflux pump inhibition
Table adapted from Uptodate and Lexicomp
*PO – By mouth; IV – Intravenous; IM; Intramuscular
** Dosing based on most frequent dosing strategies. Other dosing strategies may be available for each
individual agent

Efflux Pump Inhibitors (Approved Agents)
Agent:

Verapamil

Route of
Administration*:

PO, IV

Dosing
Strategy**:

Four times
daily
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Therapeutic
Indication:

Common and/or
Serious Adverse
Effects and Special
Considerations:

Antianginal,
antiarrhythmic,
antihypertensive

Headache, gingival
hyperplasia,
constipation,
edema, asystole,
bronchospasm,
respiratory failure,
cannot be used in
patients’ certain
cardiac disorders
(i.e. heart failure,
certain arrhythmias)

Chlorpromazine

PO, IV, IM

Four times
daily

First generation
antipsychotic

Thioridazine

PO

Four times
daily

First generation
antipsychotic

Reserpine

PO

Once daily

Hypertension,
schizophrenia

Altered cardiac
conduction,
extrapyramidal
symptoms,
anticholinergic
toxidrome,
agranulocytosis,
anemia, leukopenia,
cannot use in
patients whom use
a large amount of
CNS depressants,
increased risk of
death in elderly
patients with
dementia-related
psychosis
Dose-related QTc
prolongation,
anticholinergic
toxidrome, blood
dyscrasias, CNS
depression,
extrapyramidal
symptoms,
increased risk of
death in elderly
patients with
dementia-related
psychosis
Cardiovascular
toxicity, CNS
depression, druginduced
Parkinson’s
disease, orthostatic
hypertension, GI
toxicity

Other agents with potential as EPIs are documented in Table 1.4. These
agents, however not currently approved, have multiple promising mechanisms of
action that are ideal for efflux inhibition. These agents have shown good efficacy
at restoring susceptibility to various ATDs, however approval of an ATD
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formulation incorporating these agents has the added drawback of approval
processes for use in human patients, which has already been overcome in the
repurposed drugs used for efflux pump inhibition.
Table 1.4. Experimental efflux pump inhibitor agents and proposed mechanisms

Efflux Pump Inhibitors (Experimental Agents)
Agent:

Mechanism of
action:

Biological
Uses:

Mechanism of
efflux pump
inhibition:

Inhibits lactose
and amino acid
transport by
isolated
cytoplasmic
membrane
vesicles

Mitochondrial
proton gradient
uncoupler

DNP

Prevents the reassociation of
coupling
enzymes with
the electron
transport chain

Oxidative
phosphorylation
uncoupler

Efficiently
disrupts the
membrane
energy;
causes a
significant
increase in the
intracellular
accumulation
of antibiotic
Disrupts
proton motive
force needed
by efflux
pumps

Valinomycin

Transports
potassium ions
down their
electrochemical
gradient

SILA 421

Eliminates
plasmids

Dodecadesipeptide
antibiotic that
conducts ions
across
membranes
Reverses druginduced
resistance

Timcodar

Direct efflux
inhibition

CCCP

Increased drug
sensitivity cells
expressing P-
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References:

(Kaback,
Reeves, &
Short, 1973),
(Chevalier,
Eyraud, &
Pag, 2002)
(Pinchot,
1967),
(Zhanel,
Hoban,
Schurek, &
Karlowsky,
2004)

Depletes
potassiumgenerated
electrochemic
al gradient

(Stillwell,
2016),(Pule
et al., 2016)

Eliminates
plasmids
expressing
efflux pumps
Direct efflux
inhibition;
exact
mechanism

(Schelz et al.,
2007)
(Mullin,
Mani, &
Grossman,
2004),(Gross

glycoprotein
and MRP-1

not currently
known

man et al.,
2015)
(Opperman
& Nguyen,
2015),(K.F.,
B., S.R., &
J.C.,
1966),(Lang
mead, 2005)
(Bhardwaj,
2002; Singh,
Dubey, &
Atal,
1986),(Yaffe,
Doucette,
Walsh, &
Hoskin,
2013)
(Li et al.,
2004),(Turne
r et al., 2008)

Piperidine

Direct efflux
inhibition

Anesthetic,
vasopressor
action,
muscarinic M1
receptor agonist

Ammonioacetate moiety
extends into
the antibiotic
binding site

Piperine

P-glycoprotein,
CYP3A4, and
glucuronidation
inhibitor

Phytochemical
that acts as an
antioxidant to
scavenge for
reactive oxygen
species

Exact
mechanism is
unknown;
potentially
competes for
efflux pump
binding sites

Cholesterollowering,
improves
insulin
sensitivity

Limited data

Novel efflux
pump inhibitor

RND
substrate that
occupies the
antibioticbinding site

Berberine

Stabilizes
mRNA, inhibits
respiration via
respiratory
complex I in
mitochondria
GEQ
RND substrate
Compound that occupies
Phe-Arg-B- the antibioticNaphthbinding site
amide

(Kourtesi,
2013)

Inhalational TB Treatment and Microparticle Formulation
TB is most often considered a pulmonary disease, as this is the main source
of TB infections seen throughout the world. Treatment strategies for TB most
commonly use the oral or parenteral route of administration, however these
systemic strategies can lead to sub-therapeutic drug levels to the affected organ
system which is exaggerated in poorly vascularized regions of the lung (Pham,
Fattal, & Tsapis, 2015). Direct pulmonary delivery, however, will allow for high ATD
concentration at the primary site of infection (Hickey, Misra, & Fourie, 2013).
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Inhalation treatment strategies also have the benefit of effective alveolar
macrophage targeting when aerosols deliver particulate drug in the size range of
1 µm to 5 µm (Muttil, Wang, & Hickey, 2009). These inhalational formulations can
also decrease marked systemic side effects of the ATDs as well as the EPIs since
only a portion of the drug will reach systemic circulation.
Microparticle (MP) formulation strategies are currently of high interest in
terms of inhalable delivery of ATDs to the lungs. As previously mentioned,
particulate drugs delivered in the volumetric size range of 1 µm to 5 µm are
preferable for alveolar macrophage phagocytosis. Particle sizes ranging from 1 µm
to 3 µm in aerodynamic diameter have an additional benefit of being deposited in
the deep lung; areas rich in alveolar macrophages, thus, the most affected areas
of Mtb infection (Hickey, Misra, & Fourie, 2016). Formulation strategies have also
implemented the use of release-modifying polymers for multiple reasons. First, by
controlling the release of ATDs into the lungs this will require the patient to
administer these medications less frequently, extending the residence time of
these compounds to the affected areas (Misra et al., 2011). Second, by formulating
these ATDs and EPIs within biodegradable polymers will help to decrease
toxicities of these medications (Vibe et al., 2016).
Verapamil, Rifampicin, and Release-Modifying Polymers: Rationale for Our
Formulation
Of particular interest to this project, implementing RIF (ATD) and VER (EPI)
into a single, dry powder, MP incorporating a release-modifying polymer offers the
ability to restore ATD susceptibility via efflux pump inhibition, as previously
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discussed. This dry powder will be formulated using spray drying techniques with
the intention for delivery into the lungs with ideal size characteristics for both
alveolar macrophage targeting in addition to deep lung deposition. For releasemodifying polymers, this project will be implementing Eudragit E PO (EPO). This
polymer has many ideal properties for use in this study. It is designed to dissolve
below pH 5.0, which is below the physiologic pH of the lungs (pH of 7.38 – 7.43)
(Effros & Chinard, 1969), allowing for the polymer to swell and become a
permeable polymer matrix (Evonik, 2017). Once the polymer reaches the
macrophage microenvironment, we predict that the lower pH inside the
macrophage will allow the EPO formulation to act in an immediate release fashion,
fully releasing our payload to the site of interest. We hypothesize that because of
these properties, this polymer will be an ideal release-modifying polymer for our
MP formulation. This polymer also benefits the formulation by being an approved
product to be used in humans, although not by the pulmonary route. Other
excipients of interest are mannitol and leucine (ML). These excipients will be
formulated together to create an immediate-release formulation in contrast to our
modified-release formulation. The rationale for our formulation will be to
incorporate the EPO polymer with VER, as prolonged inhibition of efflux pumps
has been shown to increase intrabacterial levels of ATDs (Adams, Szumowski, &
Ramakrishnan, 2014). Since RIF is a concentration-dependent ATD, this agent will
be formulated with the immediate-release excipients mannitol and leucine (Gumbo
et al., 2007).
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Thesis Objectives:
1. Formulate a microparticle formulation of VER and RIF in the size range for
deep lung deposition and enhanced alveolar macrophage phagocytosis.
2. Evaluate the properties of this microparticle formulation based on size,
aerodynamic diameter, morphology, and drug release profiles.
3. Assess mammalian cell toxicity and mycobactericidal activity of formulation
using THP-1 human monocytes as well as Mycobacterium smegmatis.
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CHAPTER 2: MATERIALS AND METHODS
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Materials
Chemicals for dry powder formulation including VER, L-leucine, and Dmannitol were obtained from Sigma Aldrich (St. Louis, MO). RIF was obtained from
the Tokyo Chemical Industy (Chuo-ku, Tokyo, Japan), and Eudragit E PO was
obtained from Evonik Health Care (Essen, Germany). Chemicals and buffers for
HPLC analysis were obtained from the following companies; sodium phosphate
monobasic from J.T. Baker Chemical Co (Phillipsburg, NJ), potassium phosphate
and OmniSolv acetonitrile for HPLC gradient analysis, spectrophotometry, and gas
chromatography from EMD Millipore (St. Charles, MO). The dialysis membrane for
the dry powder dissolution analysis, SnakeSkin Dialysis Tubing 10K MWCO 16
mm dry internal diameter, was obtained from Thermo Fisher Scientific (Waltham,
MA). Regarding in vitro cytotoxicity studies, THP-1 monocyte cell culture was a
generous donation from Dr. Eric Neumann’s laboratory. RPMI 1640 media (high
glucose with L-Glutamine and HEPES) for THP-1 cell culture was obtained from
ATCC (Manassas, VA). [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS for the toxicity assay was
obtained from Promega (Madison, WI). For in vitro efficacy studies, Mycobacterium
smegmatis was obtained from ATCC (Manassas, VA). Media and agar for
Mycobacterium smegmatis (M. smeg), Middlebrook 7H9 with ADC and
Middlebrook 7H10 with OADC respectively, were obtained from Becton Dickinson
and Company (Sparks, MD).
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Microparticle Formulation
Microparticles were prepared using the Buchi-290 mini-spray dryer. For
both drugs (VER and RIF), dry powders with individual drugs were formulated. Two
types of formulations of VER were made, one with an altered-release formulation
utilizing EPO, and another as an immediate release formulation utilizing ML. One
formulation of RIF was made which utilized an immediate release formulation of
ML. RIF was solubilized in dimethylsulfoxide (DMSO) (10mg/mL), and VER was
solubilized using methanol (MeOH) (10mg/mL). EPO was subsequently added to
the above formulation by dissolving increasing concentrations into diH2O at pH <
5.0. pH was adjusted to be < 5.0 for every 10 mg EPO powder added to solution
with 1M hydrochloric acid. ML did not require pH adjustments as these excipients
are readily water soluble. We used ML in a ratio of 1:1 mannitol:leucine for the
immediate release formulations. Specific formulation parameters are as follows;
RIF:ML was formulated using 50 mg of RIF powder 25 mg of mannitol, and 25 mg
of leucine dissolved in 100 mL of diH2O. VER:ML was formulated using 25 mg of
VER powder with 37.5 mg of mannitol and 37.5 mg of leucine dissolved in 100 mL
of diH2O. VER:EPO was formulated 25 mg of VER and 75 mg of EPO which was
dissolved in 100 mL of pH-adjusted diH2O. For the mixed powder formulations, we
wanted to create a 3:1 RIF:VER ratio of the active agents, based on previous data
as well as closely representing commonly used oral dosages. This was achieved
by combining the spray dried powders in a way that achieved 60% w/w RIF powder
with 40% w/w VER powder. These powders were then homogeneously mixed
using a 500 µm sieve. RIF:ML, VER:ML powders will from here on be referred to
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as RMVM mixed powders. RIF:ML, VER:EPO powders will from here on be
referred to as RMVE mixed powders.
Microparticle Characterization
Dry powders formulated using spray drying were characterized for their
volumetric particle size, aerodynamic diameter, particle morphology, and drug
loading as follows.
Drug Quantification: HPLC Method
Drug loading and mixing efficiency of the microparticles were quantified
using an Agilent 1200 high performance liquid chromatography (HPLC) system
using a Phenomenex Gemini-NX 5 micron, C18, 110 Å 150 X 4.60 mm column.
We developed an HPLC method to detect both VER and RIF samples, which was
used for all samples. The initial isocratic phase consisted of 97% acetonitrile (ACN)
and 3% potassium phosphate (KPhos) buffer at pH of 7.7 and remained isocratic
until 2.0 minutes. The first gradient phase was set between 2.0 and 2.2 minutes to
the following isocratic phase. The second isocratic phase consisted of 55% ACN
and 45% KPhos buffer at pH of 7.7 and remained isocratic until 7.0 minutes. The
second gradient phase was set between 7.0 and 7.2 minutes to the following
isocratic phase. The third isocratic phase consisted of 63% KPhos buffer at pH of
7.7 and 37% KPhos buffer at pH 5.2 and remained isocratic until 10.0 minutes.
The final gradient phase was set between 10.0 and 11.0 minutes to the final
isocratic phase. The final isocratic phase was the same as the first in order to
equilibrate the column for the next sample, which again consisted of 97% ACN and
3% KPhos buffer at pH of 7.7 for a total run time of 15 minutes. All samples were
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analyzed at 230 nm wavelength, and 50 microliters of sample were injected per
run. All samples were analyzed in duplicate. RIF had an elution time of 5.9-6.1
minutes and VER had an elution time of 8.9-9.1 minutes at a flow rate of 1.5
milliliters per minute. All powder samples were prepared using 50% acetonitrile
and 50% diH2O. Individual standard curves were made for VER and RIF in the
concentration range of 0.1-25 ug/mL for every HPLC analysis.
Volumetric particle sizing
Sizing of the particles was performed on a Malvern Mastersizer 3000
(Malvern Instruments Ltd. Malvern, UK) with an Aero S dry powder disperser unit.
Measurements were taken in triplicate using a standard operating procedure
(SOP) developed in our laboratory.
Aerodynamic particle sizing
Aerosol performance of the powders was characterized using a Next
Generation Impactor (NGI). Five milligrams of mixed powder were loaded into
hydroxypropylmethylcellulose (HPMC) capsules and pierced using the Aerolizer
device. These powders were then aerosolized through the NGI at a flow rate of 60
L/min for 5-7 seconds. Each powder sample was run in triplicate, for a total of 15
milligrams per powder. After the 3 samples were ran through the device, powders
at each stage, the Aerolizer inhaler device, capsules, rubber adapter, and all
stages were collected using 1.5 milliliters of diH2O and subsequently diluted 1:1 in
acetonitrile for maintenance before HPLC analysis. Samples were then diluted
1:10 in acetonitrile and ran using the VER and RIF combined HPLC protocol.
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Particle Morphology: SEM Imaging
The surface morphology of the particles was performed using scanning
electron microscopy. In short, samples of each individual powder and mixed
powder were desiccated thoroughly overnight. These powders were then lightly
brushed onto SEM-specific sampling pegs coated with a sticky tape. Images were
captured using a Zeiss Sigma FE-SEM; images were acquired with the SE2
detector using a "classical" SEM detection of secondary electrons with an
acceleration voltage of 1.00 kV. Each powder was imaged at 3000X magnification
and 7250X magnification.
Drug Release
Release of the drug powders were performing using a modified dialysis
membrane protocol. Eight centimeters of SnakeSkin Dialysis Tubing was cut and
soaked in 0.05 M sodium phosphate buffer (NaPhos) with an adjusted pH of 7.4 to
match that of lung fluid. A 50 mL conical tube was filled with 30 mL of this adjustedpH solution with a small stir bar, placed on a tube stand on top of a stir plate inside
of a 37o Celsius benchtop incubator. Three milligrams of mixed powder were then
dissolved into three milliliters of the pH-adjusted NaPhos solution in a 5 mL
polypropylene tube and lightly vortexed. One side of the cut dialysis tubing was
clamped using a 3 cm dialysis tube clamp. The three milliliters of drug solution
were then pipetted carefully into the clamped tubing, and the open end of the
dialysis membrane was then clamped after all drug solution was successfully
transferred. This clamped dialysis tubing was then submerged into the 30 mL
buffer solution within the 50 mL conical tube. Samples of 1 mL from the 30 mL
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buffer solution were taken at the time points 0 minutes, 15 minutes, 30 minutes, 1
hour, 2 hours, 4 hours and finally 24 hours. After sampling, the buffer solution was
replaced with 1 mL of fresh buffer solution.
Microparticle In vitro Cytotoxicity: Toxicity Studies
In vitro cytotoxicity of the powders was determined using an MTS assay in
the THP-1 monocyte cell culture. Each of the mixed powders were resuspended
and vortexed for 3 minutes in RPMI 1640 medium at different concentrations (1.00.0625 mg/mL). The THP-1 cells were differentiated into macrophages by phorbol
12-myristate 13-acetate (PMA) 20 nanomolar in a 96 well cell-culture plate for 24
hours and allowed time to recover after PMA exposure for an additional 48 hours.
After exposing the cells to the resuspended dry powders for 24 hours, the drug
solution was pipetted off and replaced with 100 microliters of PBS. Subsequently
the MTS reagent was added and allowed to incubate for 4 hours at 37o C with 5%
CO2. Absorbance was then read at 490 nm. Loss in cell viability was measured
by a reduction in metabolic activity using MTS.
Microparticle Bactericidal Activity: Efficacy Studies
The efficacy of the spray dried powders against M. smeg was tested in vitro
after 3 hours of incubation at 37°C. We infected PMA-differentiated THP-1 cells
(differentiation above) with M. smeg for 3 hours. The M. smeg CFU was chosen
based on our preliminary studies of in vitro infection of macrophages: we showed
that the best multiplicity of infection (MOI) was one (5x105 THP-1 cells/mL cells
confluency in a 12 well plate). After infection, we washed the infected cells 3 times
in sterile PBS buffer in order to get rid of any extracellular M. smeg that did not
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manage to be phagocytosed. Different concentrations of the powders were
prepared in Middlebrook 7H9 broth medium (40-5 µg/mL of the RIF component)
and added to infected PMA-differentiated THP-1 cells. After the aforementioned
incubation time point was achieved, we lysed the THP-1 cells using 0.05% SDS
buffer in diH2O and plated the bacteria on Middlebrook 7H10 agar plates for CFU
counts. These plates were incubated for 48 hours at 37°C and CFU were
determined.
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CHAPTER 3: RESULTS, DISCUSSION, AND FUTURE DIRECTIONS
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RESULTS
Drug loading efficiency
Using the combined drug HPLC protocol, the loading and percentage
loading efficiency was quantified. For the RIF:ML formulation an average loading
of 517.5 micrograms of RIF per milligram of powder was achieved, with an average
loading efficiency of 103.4%±0.8%.

For the VER:ML formulation an average

loading of 288.1 micrograms of VER per milligram of powder was achieved with
an average loading efficiency of 115.2%±4.1%. For the VER:EPO formulation an
average loading of 252.2 micrograms of VER per milligram of powder was
achieved with an average loading efficiency of 100.9%±3.7%.
Mixing efficiency
Using the combined drug HPLC protocol, the efficiency of dry powder
mixing was quantified and assessed for proper drug ratio as well as percent mixing
efficiency. We expected to have 300 micrograms of RIF and 100 micrograms of
VER per 1 milligram of mixed powder after accounting for amount of excipient in
each formulation. For the RMVM powder, we achieved 232.04 micrograms of RIF
and 99.56 micrograms of VER per milligram of mixed powder. This gives us a
77.3% mixing efficiency of RIF and a 99.6% mixing efficiency of VER. This also
gives us a RIF:VER drug ratio of 2.33:1 (theoretical ratio 3:1). For the RMVE
powder, we achieved 227.65 micrograms of RIF and 88.16 micrograms per
milligram of mixed powder. This gives us a 75.9% mixing efficiency of RIF and an
88.2% mixing efficiency of VER. This also gives us a RIF:VER drug ratio of 2.58:1
(theoretical ratio 3:1).
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Volumetric size distribution
After formulation of our individual powders, we used the Malvern
Mastersizer 3000 to determine their volumetric size distribution (as described
above). Approximately 2 milligrams of the spray dried powders were passed
through the Aero S dry powder disperser of the Mastersizer in triplicate to get a
size distribution (Figure 3.1).
We mixed the different drug containing powders that would give a 1:3 ratio
of RIF and VER. This drug ratio is based on the literature and also the oral daily
doses of each drug (Parumasivam et al., 2016). After mixing the powders
homogenously using a sieving technique, we determined the volumetric size
distribution using the above method used for single-drug powders (Figure 3.2).
The volumetric size distribution data for all of the formulated powders (individual
and mixed) can be found in Table 3.1.
Briefly, we were able to determine that the volumetric size distribution of
50% (D-50) of all spray dried powders fell between 1.77 and 2.63 µm. All powders
also demonstrated a span of less than 2 µm except for the RMVE powder, which
had a span of 5.74 µm. We attribute this larger span to clumping and potential
agglomeration of this particular mixed powder.
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Figure 3.1. Spray dried powder (individual drug) volumetric size distribution. Individual powders which were
analyzed were RIF with ML (a), VER with ML (b) and VER with EPO (c).
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Figure 3.2. Spray dried powder (mixed drugs) volumetric size distribution
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Table 3.1. Volumetric size distributions and span of all the formulated powders

Powder Sample
RIF ML
VER ML
VER EPO
RIF ML:VER ML
RIF ML:VER EPO

D-50
2.63±.012 µm
1.77±0.005 µm
2.22±0.022 µm
2.26±0.029 µm
2.48±0.144 µm

Span
1.65±0.018 µm
1.27±0.032 µm
1.45±0.237 µm
1.45±0.015 µm
5.74±5.29 µm

Aerodynamic diameter
After mixing the individual drug containing powders, we determined that
an ideal formulation would consist of a modified-release EPI in combination with
an immediate release ATD. Our goal is to achieve elevated anti-TB drug
concentration inside the bacteria, with prolonged efflux pump inhibition (Adams et
al., 2014); this will be achieved with an immediate release of RIF due to the
concentration-dependent killing activity against Mycobacterium tuberculosis
(Gumbo et al., 2007). We also created an immediate release formulation of both
the EPI and ATD for comparability of dissolution, efficacy, and toxicity. The mixed
powders of ‘RIF:ML, VER:EPO’ as well as ‘RIF:ML, VER:ML’ were chosen for
aerodynamic testing. After aerosolizing 15 mg of the mixed powder through the
NGI (as previously mentioned), the mass median aerodynamic diameter (MMAD)
and geometric standard deviation (GSD) were determined using the combined
HPLC protocol, which allowed us to analyze RIF and VER together for both
mixed powder formulations. For the RMVM mixed powder we determined the
MMAD to be 3.05±0.095 µm with a GSD of 1.87±0.155 µm for RIF and
determined the MMAD to be 2.45±0.175 µm with a GSD of 1.93±0.025 µm for
VER. For the RMVE mixed powder we determined the MMAD to be 3.01±0.08
µm with a GSD of 1.87±0.035 µm for RIF and we determined the MMAD to be
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4.95±0.015 µm with a GSD of 2.35±0.02 µm for VER. For the RMVM mixed
powder, we determined the fine particle fraction (FPF) of RIF to be 85.6% and
the FPF of VER to be 84.3%. For the RMVE mixed powder, we determined the
FPF of RIF to be 89.3% and the FPF of VER to be 70.8%. The overall distribution
of particle deposition for RIF and VER in each of the mixed powders is illustrated
in Figure 3.3.
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Figure 3.3. Aerodynamic Diameter Data (NGI) for each of the mixed powders. RIF and VER are
represented, respectively, in (a) and (b) the aerodynamic performance of the RIF:ML, VER:ML mixed
powders and (c) and (d) the aerodynamic performance of the RIF:ML, VER:EPO mixed powders. The Fine
particle fraction, that potentially gets depositied in the deep lung, is represented in green bars.
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Particle Morphology
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Figure 3.4. Scanning Electron Microscope Images of Individual Powders. SEM images at 3.0K times
magnification and 7.25K times magnification, respectively, of (a) and (b) RIF:ML, (c) and (d) VER:ML, and
(e) and (f) VER:EPO.
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a
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Figure 3.5. Scanning Electron Microscope Images of Mixed Powders. SEM images at 3.0K and 7.25K times
magnification, respectively, of (a) and (b) RMVM, and (c) and (d) RMVE

To determine the particle morphology of each formulation, we subjected
powders to scanning electron microscopy (SEM) imaging. Figure 3.2 represents
the SEM images captured of the individual drug powders. Both RIF and VER
formulations using ML showed irregularly shaped particles in the size range that is
representative of the volumetric diameter data. The VER formulation using EPO
created spherical, regularly shaped particles that are also representative of the
volumetric diameter data. Figure 3.3 represents SEM images of the mixed drug
powders. Similar to figure 3.2, the mixed powders showed irregularly shaped
particles in the RMVM mixed powder, and irregularly shaped particles interspersed
with spherical, regularly shaped particles in the RMVE mixed powder.
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Drug Release
In order to determine the in vitro drug release of the mixed powders, we
subjected powders to the above-mentioned drug release protocol. In the RMVM
mixed powder, we were able to achieve 95.6% drug release of the RIF component
and 83.0% drug release of the VER component at 24 hours (figure 3.6c). In the
RMVE mixed powder, we were able to achieve 110.6% drug release of the RIF
component and 86.9% drug release of the VER component at 24 hours (figure
3.6d). The most noticeable difference of formulation performance, however, was
at 4 hours. With the RMVM mixed powder, both drugs showed approximately 70%
drug release at 4 hours. With the RMVE mixed powder, however, the RIF
component achieved only 60% drug release at 4 hours where the VER component
was able to achieve approximately 80% release. This data is depicted in figure
3.6a and 3.6b; with data shown to 4 hours because this is data that demonstrated
differences in the release pattern when comparing the two mixed powders.
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Figure 3.6. Drug Release Data. The 4-hour data is represented in (a) for RMVM, and for (b) RMVE. The 24hour data is represented in (c) for RMVM and (d) for RMVE.
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Microparticle In vitro Cytotoxicity
Once all powders were formulated and mixed, the toxicity of the
formulations against PMA differentiated THP-1 cells (Human monocyte-like cells)
was evaluated. We subjected THP-1 cells to various concentrations of each of the
mixed formulations for 24 hours, and then washed once with PBS to remove
excessive drug powders. Data is shown in figure 3.5, with each bar representing
the percent cellular viability. The RMVM immediate release formulation at 1
milligram per milliliter after 24 hours of exposure led to achieve a 14.47% ± 0.29%
THP-1 cell viability. The RMVM formulation at 500 micrograms per milliliter led to
a 45.42% ± 2.54% viability after 24 hours of exposure. The other lower
concentrations of the RMVM formulations (250 µg/mL, 125 µg/mL, and 62.5
µg/mL) achieved over 99% cellular viability (Figure 3.7a). The RMVE sustained
release formulation at 1 milligram per milliliter led to a 36.20% ± 3.23% viability
after 24 hours of exposure. The RMVE formulation at 500 micrograms per milliliter
led to a 29.39% ± 2.65% viability. The RMVE formulation at 250 micrograms per
milliliter allowed the THP-1 cells to achieve a 25.01% ± 1.84% viability. The RMVE
formulation at 125 micrograms per milliliter allowed the THP-1 cells to achieve a
23.69% ± 1.79% viability. Finally, the RMVE formulation at 62.5 micrograms per
milliliter allowed the THP-1 cells to achieve a 26.05% ± 3.80% viability (Figure
3.7b).
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Figure 3.7. In vitro Cytotoxicity Data. Data is shown as percent viability of the THP-1 cells after 24 hours of
drug exposure. (a) RIF:ML and VER:ML data at given concentrations (b) RIF:ML and VER:EPO data at given
different concentrations
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Microparticle Bactericidal Activity in Infected Cells
In order to determine the bactericidal activity of our mixed powder
formulation, THP-1 differentiated cells were infected with Mycobacterium
smegmatis, a Mtb surrogate (BSL-1 organism). After the THP-1 cells were infected
with M. smeg for 2 hours, different concentrations of powder formulations were
exposed to the infected cells for 1 hour. The infected cells were washed twice in
PBS, lysed in 0.05% SDS buffer, and colony forming units (CFUs) were
determined. This data is depicted in Figure 3.6. For controls, one well of THP-1
cells were infected with M. smeg and exposed to no drug powders. This control
well resulted in 5.4 X 105 CFUs of M. smeg after infection. For the RMVM
immediate release powder exposure, a concentration of 5 micrograms per milliliter
resulted in 1.0 x 105 CFUs; at a concentration of 10 micrograms per milliliter
resulted in 9.0 X 104 CFUs; at a concentration of 20 micrograms per milliliter
resulted in 3.8 X 104 CFUs; and at a concentration of 40 micrograms per milliliter
resulted in 4.0 X 104 CFUs. For the RMVE sustained release powder, a
concentration of 5 micrograms per milliliter resulted in 4.0 X 105 CFUs; at a
concentration of 20 micrograms per milliliter resulted in 1.1 X 105 CFUs; at a
concentration of 20 micrograms per milliliter resulted in 1.2 X 104 CFUs; and at a
concentration of 40 micrograms per milliliter resulted in 1.4 X 104 CFUs.
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RMVM and RMVE In vitro Bactericidal Activity
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Figure 3.8. In vitro bactericidal activity. RIF:ML and VER:ML immediate release and RIF:ML and VER:EPO
sustained release formulation data

DISCUSSION
The necessity of combating MDR and XDR-TB cannot be overstated.
Understanding novel mechanisms utilized by Mycobacterium tuberculosis to
evade bactericidal activity of our current antibiotic regimens, such as efflux pump
overexpression, has been a crucial step in the right direction. Additionally, the
strides taken for pulmonary delivery for TB treatment has been a pivotal goal which
will hopefully be implemented in TB endemic regions to achieve global control of
this extremely debilitating disease.
We have demonstrated the feasibility to formulate microparticles (dry
powders) that are 1-3 microns in aerodynamic diameter, the correct size range to
reach the deep lung (Misra et al., 2011). Furthermore, we have shown excellent
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drug loading efficiency for both RIF and VER as well as demonstrated
homogenous mixing efficiency to create the ideal RIF:VER drug ratio. This
formulation will potentially facilitate therapeutic drug concentration to the intended
site of action in the lung without the requirement for high ATD oral or parenteral
administration.
Interestingly, our formulations displayed vastly different aerodynamic
performance regarding the VER component. The “immediate release” formulation
of RIF achieved an aerodynamic size of 3.05 micron and VER achieved an
aerodynamic size of 1.87 micron. The “sustained-release” formulation of RIF
achieved an aerodynamic size of 3.01 micron, similar to the immediate release;
however VER achieved an aerodynamic size of 4.95 micron, drastically different
from the immediate release formulation. This data contradicts the volumetric
diameter data for the same formulation; the aerodynamic diameter of the VER
component is higher compared to the volumetric size distribution, possibly due to
the differences in the density of MP containing EPO. Another interesting result was
the release data. It appears that the Eudragit polymer affected the release of RIF,
delaying its release by approximately 10% at 4 hours when compared to the
immediate release formulation. The “sustained release” formulation also displayed
increased VER release at 4 hours to 80% release. There could be many reasons
for this contradicting result and further studies are required to fully understand the
release mechanism from our formulations.
Regarding the in vitro performance, the “sustained release” formulation was
more toxic to THP-1 cells than the “immediate release” formulation at the same
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concentrations. As shown in figure 3.7, at any concentration the RMVE formulation
was able to achieve only approximately 20 – 40% cellular viability, whereas the
RMVM formulation was able to achieve over 99% viability at concentrations of 250
micrograms per milliliter or lower. As previously mentioned, the only difference
between these formulations is the Eudragit E PO polymer, which could be
attributed to the increase in toxicity. Interestingly, the “sustained release”
formulation displayed greater viability at higher concentrations. This could,
however, be due to the residual drug left after the washing step. As the assay is
read at 490 nm, residual rifampicin remained in the wells of the “sustained release”
formulation, and could have contributed to this higher absorbance. Therefore, this
study needs to be repeated with a modified washing protocol. Bactericidal activity
was also superior in the immediate release RMVM formulation at lower
concentrations, however the bactericidal activity of the sustained release RMVE
formulation surpassed that of RMVM at 20 and 40 micrograms per milliliter.
Whether the in vitro performance of these powders is statistically significant would
require repeating the in vitro studies.
FUTURE DIRECTIONS
This project would benefit from further tests to better determine the
characteristics of our inhalable dry powder formulation. First, by assessing the drug
release of our formulation at pH’s below the threshold of Eudragit E PO’s
dissolution, we could determine if a “burst” release profile was present in the EPO
formulations, which was hypothesized to occur once the microparticle reached the
macrophage microenvironment. Next, in vitro testing could be repeated to
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determine the effectiveness and toxicity of our formulations, in which various
concentrations and sampling times could be tested to further strengthen the
conclusion of this project. Finally, the future goal of this dry powder formulation
containing an ATD and an EPI is to display in vivo activity against Mtb in a
preclinical TB infection model.

48

REFERENCES
1. Adams, K. N., Szumowski, J. D., & Ramakrishnan, L. (2014). Verapamil,
and its metabolite norverapamil, inhibit macrophage-induced, bacterial
efflux pump-mediated tolerance to multiple anti-tubercular drugs. Journal
of Infectious Diseases, 210(3), 456–466.
https://doi.org/10.1093/infdis/jiu095
2. Adams, K. N., Takaki, K., Connolly, L. E., Wiedenhoft, H., Winglee, K.,
Humbert, O., … Ramakrishnan, L. (2011). Drug tolerance in replicating
mycobacteria mediated by a macrophage-induced efflux mechanism. Cell,
145(1), 39–53. https://doi.org/10.1016/j.cell.2011.02.022
3. Bhardwaj, R. K. (2002). Piperine, a Major Constituent of Black Pepper,
Inhibits Human P-glycoprotein and CYP3A4. Journal of Pharmacology and
Experimental Therapeutics, 302(2), 645–650.
https://doi.org/10.1124/jpet.102.034728
4. CDC. (2014a). TB Fact sheets Extensively Drug-Resistant Tuberculosis
(XDR TB). CDC.
5. CDC. (2014b). TB Treatment. CDC.
6. Chevalier, J., Eyraud, A., & Pag, J. (2002). Inhibitors of antibiotic efflux
pump in resistant Enterobacter aerogenes strains, 293, 1370–1373.
7. Costa-Gouveia, J., Aínsa, J. A., Brodin, P., & Lucía, A. (2017). How can
nanoparticles contribute to antituberculosis therapy? Drug Discovery
Today, 22(3), 600–607. https://doi.org/10.1016/j.drudis.2017.01.011
8. Effros, R. M., & Chinard, F. P. (1969). The in vivo pH of the extravascular

49

space of the lung. The Journal of Clinical Investigation, 48(11), 1983–
1996. https://doi.org/10.1172/JCI106164
9. Ehrt, S., & Schnappinger, D. (2009). Mycobacterial survival strategies in
the phagosome: Defence against host stresses. Cellular Microbiology,
11(8), 1170–1178. https://doi.org/10.1111/j.1462-5822.2009.01335.x
10. Evonik. (2017). Eudragit® Setting benchmarks in oral solid dosage forms
since 1954. Sales Material. https://doi.org/10.1007/s00334-015-0543-x
11. Grossman, T. H., Shoen, C. M., Jones, S. M., Jones, P. L., Cynamon, M.
H., & Locher, C. P. (2015). The efflux pump inhibitor timcodar improves
the potency of antimycobacterial agents. Antimicrobial Agents and
Chemotherapy, 59(3), 1534–1541. https://doi.org/10.1128/AAC.04271-14
12. Gumbo, T., Louie, A., Deziel, M. R., Liu, W., Parsons, L. M., Salfinger, M.,
& Drusano, G. L. (2007). Concentration-dependent Mycobacterium
tuberculosis killing and prevention of resistance by rifampin. Antimicrobial
Agents and Chemotherapy, 51(11), 3781–3788.
https://doi.org/10.1128/AAC.01533-06
13. Gupta, S., Cohen, K. A., Winglee, K., Maiga, M., Diarra, B., & Bishai, W.
R. (2014). Efflux inhibition with verapamil potentiates bedaquiline in
mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy,
58(1). https://doi.org/10.1128/AAC.01462-13
14. Gupta, S., Tyagi, S., Almeida, D. V., Maiga, M. C., Ammerman, N. C., &
Bishai, W. R. (2013). Acceleration of tuberculosis treatment by adjunctive
therapy with verapamil as an efflux inhibitor. American Journal of

50

Respiratory and Critical Care Medicine, 188(5), 600–607.
https://doi.org/10.1164/rccm.201304-0650OC
15. Hickey, A. J., Misra, A., & Fourie, P. B. (2013). Dry powder antibiotic
aerosol product development: Inhaled therapy for tuberculosis. Journal of
Pharmaceutical Sciences. https://doi.org/10.1002/jps.23705
16. Hickey, A. J., Misra, A., & Fourie, P. B. (2016). Drug Delivery Systems for
Tuberculosis Prevention and Treatment. Drug Delivery Systems for
Tuberculosis Prevention and Treatment.
https://doi.org/10.1002/9781118943182
17. K.F., I., B., J., S.R., O., & J.C., W. (1966). Mechanism of cardiovascular
actions of 1-(1-phenylcyclohexyl)piperidine hydrochloride (phencyclidine).
British Journal of Pharmacology and Chemotherapy, 28(1), 73–83.
Retrieved from
http://www.embase.com/search/results?subaction=viewrecord&from=expo
rt&id=L87087334%0Ahttp://rug.on.worldcat.org/atoztitles/link/?sid=EMBA
SE&issn=03660826&id=doi:&atitle=Mechanism+of+cardiovascular+action
s+of+1-%281-phenylcyclohexyl%29piperidine+hydrochlor
18. Kaback, H. R., Reeves, J. P., & Short, S. A. (1973). Mechanisms of active
transport in isolated bacterial membrane vesicles. Journal of Biological
Chemistry.
19. Koch, A., Mizrahi, V., & Warner, D. F. (2014). The impact of drug
resistance on Mycobacterium tuberculosis physiology: What can we learn
from rifampicin? Emerging Microbes and Infections, 3.

51

https://doi.org/10.1038/emi.2014.17
20. Kourtesi, C. (2013). Microbial Efflux Systems and Inhibitors: Approaches
to Drug Discovery and the Challenge of Clinical Implementation. The
Open Microbiology Journal, 7(1), 34–52.
https://doi.org/10.2174/1874285801307010034
21. Langmead, C. J. (2005). Probing the molecular mechanism of interaction
between AC-42 and the muscarinic M1 receptor: Direct pharmacological
evidence that AC-42 is an allosteric agonist. Molecular Pharmacology,
69(1), 236–246. https://doi.org/10.1124/mol.105.017814
22. Li, Z., Abidi, P., Kong, W., Jiang, J.-D., Si, S., Wang, Z., … Wang, Y.
(2004). Berberine is a novel cholesterol-lowering drug working through a
unique mechanism distinct from statins. Nature Medicine, 10(12), 1344–
1351. https://doi.org/10.1038/nm1135
23. Marino, S., Mattila, J. T., Kirschner, D. E., Flynn, J. L., Linderman, J. J., &
Cilfone, N. A. (2014). Macrophage Polarization Drives Granuloma
Outcome during Mycobacterium tuberculosis Infection. Infection and
Immunity, 83(1), 324–338. https://doi.org/10.1128/iai.02494-14
24. Misra, A., Hickey, A. J., Rossi, C., Borchard, G., Terada, H., Makino, K.,
… Colombo, P. (2011). Inhaled drug therapy for treatment of tuberculosis.
Tuberculosis, 91(1), 71–81. https://doi.org/10.1016/j.tube.2010.08.009
25. Mullin, S., Mani, N., & Grossman, T. H. (2004). Inhibition of Antibiotic
Efflux in Bacteria by the Novel Multidrug Resistance Inhibitors Inhibition of
Antibiotic Efflux in Bacteria by the Novel Multidrug Resistance Inhibitors

52

Biricodar ( VX-710 ) and Timcodar ( VX-853 ), 48(11), 4171–4176.
https://doi.org/10.1128/AAC.48.11.4171
26. Muttil, P., Wang, C., & Hickey, A. J. (2009). Inhaled drug delivery for
tuberculosis therapy. Pharmaceutical Research.
https://doi.org/10.1007/s11095-009-9957-4
27. Nicas, M., Nazaroff, W. W., & Hubbard, A. (2005). Toward understanding
the risk of secondary airborne infection: Emission of respirable pathogens.
Journal of Occupational and Environmental Hygiene, 2(3), 143–154.
https://doi.org/10.1080/15459620590918466
28. O’Garra, A., Redford, P. S., McNab, F. W., Berry, M. P. R., Bloom, C. I., &
Wilkinson, R. J. (2013). The Immune Response in Tuberculosis. Annual
Review of Immunology (Vol. 31). https://doi.org/10.1146/annurevimmunol-032712-095939
29. Opperman, T. J., & Nguyen, S. T. (2015). Recent advances toward a
molecular mechanism of efflux pump inhibition. Frontiers in Microbiology,
6(MAY), 1–16. https://doi.org/10.3389/fmicb.2015.00421
30. Parumasivam, T., Chan, J. G. Y., Pang, A., Quan, D. H., Triccas, J. A.,
Britton, W. J., & Chan, H. K. (2016). In Vitro Evaluation of Inhalable
Verapamil-Rifapentine Particles for Tuberculosis Therapy. Molecular
Pharmaceutics, 13(3), 979–989.
https://doi.org/10.1021/acs.molpharmaceut.5b00833
31. Pham, D. D., Fattal, E., & Tsapis, N. (2015). Pulmonary drug delivery
systems for tuberculosis treatment. International Journal of

53

Pharmaceutics. https://doi.org/10.1016/j.ijpharm.2014.12.009
32. Philips, J. A., & Ernst, J. D. (2011). Tuberculosis Pathogenesis and
Immunity. Annual Review of Pathology: Mechanisms of Disease, 7(1),
353–384. https://doi.org/10.1146/annurev-pathol-011811-132458
33. Pinchot, G. B. (1967). The Mechanism of Uncoupling of Oxidative
Phosphorylation by 2,4-Dinitrophenol. October, 242(20).
34. Price, D. N., & Muttil, P. (2016). Directed Intervention and
Immunomodulation against Pulmonary Tuberculosis. In Drug Delivery
Systems for Tuberculosis Prevention and Treatment.
https://doi.org/10.1002/9781118943182.ch18
35. Pule, C. M., Sampson, S. L., Warren, R. M., Black, P. A., van Helden, P.
D., Victor, T. C., & Louw, G. E. (2016). Efflux pump inhibitors: Targeting
mycobacterial efflux systems to enhance TB therapy. Journal of
Antimicrobial Chemotherapy, 71(1), 17–26.
https://doi.org/10.1093/jac/dkv316
36. Russell, D. G., Barry, C. E., & Flynn, J. L. (2010). Tuberculosis : What We
Don ’ t Know, 328(May), 852–857.
37. Schelz, Z., Martins, M., Martins, A., Viveiros, M., Molnar, J., & Amaral, L.
(2007). Elimination of plasmids by SILA compounds that inhibit efflux
pumps of bacteria and cancer cells. In Vivo, 21(4), 635–640.
38. Singh, J., Dubey, R. K., & Atal, C. K. (1986). Piperine-Mediated Inhibition
of Glucuronidation Activity in Isolated Epithelial Cells of the Guinea-Pig
Small Intestine : Evidence that Piperine Lowers the Endogeneous UDP-

54

Glucuronic Acid Content. The Journal of Pharmacology and Experimental
Therapeutics, 236, 488–493.
https://doi.org/10.1002/hbm.22068.Automated
39. Stillwell, W. (2016). Chapter 19-Membrane Transport. An Introduction to
Biological Membranes (Second Edition), 423–451.
https://doi.org/10.1016/B978-0-12-800047-2.00013-9
40. Sun, J., Deng, Z., & Yan, A. (2014). Bacterial multidrug efflux pumps:
Mechanisms, physiology and pharmacological exploitations. Biochemical
and Biophysical Research Communications.
https://doi.org/10.1016/j.bbrc.2014.05.090
41. Turner, N., Li, J., Gosby, A., To, S. W. C., Cheng, Z., Miyoshi, H., … Li, J.
(2008). Berberine and Its More Biologically Available Derivative,
Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I. Diabetes,
57(5), 1414–1418. https://doi.org/10.2337/db07-1552.Additional
42. Vibe, C. B., Fenaroli, F., Pires, D., Wilson, S. R., Bogoeva, V., Kalluru, R.,
… Hildahl, J. (2016). Thioridazine in PLGA nanoparticles reduces toxicity
and improves rifampicin therapy against mycobacterial infection in
zebrafish. Nanotoxicology, 10(6), 680–688.
https://doi.org/10.3109/17435390.2015.1107146
43. WHO. (2017). The Top 10 causes of Death.
https://doi.org//entity/mediacentre/factsheets/fs310/en/index.html
44. Yaffe, P. B., Doucette, C. D., Walsh, M., & Hoskin, D. W. (2013). Piperine
impairs cell cycle progression and causes reactive oxygen species-

55

dependent apoptosis in rectal cancer cells. Experimental and Molecular
Pathology, 94(1), 109–114. https://doi.org/10.1016/j.yexmp.2012.10.008
45. Zhanel, G. G., Hoban, D. J., Schurek, K., & Karlowsky, J. A. (2004). Role
of efflux mechanisms on fluoroquinolone resistance in Streptococcus
pneumoniae and Pseudomonas aeruginosa. International Journal of
Antimicrobial Agents, 24(6), 529–535.
https://doi.org/10.1016/j.ijantimicag.2004.08.003
46. Zhang, Y., & Yew, W. W. (2009). STATE OF THE ART Mechanisms of
drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis,
13(11), 1320–1330.

56

APPENDICES

57

Appendix 1: Inhalation Aerosols: Physical and Biological Basis for
Therapy, Third Edition Hickey, A.J., and Mansour H.M., (2019)

Chapter 23: Inhaled therapeutics against TB: the promise of pulmonary treatment
and prevention strategies in the clinic

Dominique N. Price, Nitesh K. Kunda, Elliott K. Miller, and Pavan Muttil

Contributions to this Publication:
Challenges of inhaled therapy to the clinic
“One of the challenges with the pulmonary route relates to the cost of the
combined device-formulation product and the ability of patients to use inhalers
consistently and properly to achieve treatment compliance. Since TB primarily
affects low- and middle-income countries, it is important to develop treatment and
preventive strategies that are cost-effective. Current inhalers in the market (for
diseases such as asthma) are expensive and complicated to use without proper
medical supervision; this makes it challenging to use a similar strategy against
TB, especially if it requires long-term inhaler use. Adherence to treatment also
entails patient’s satisfaction with the inhaler device, which is influenced by
convenience of daily use, patient age, adverse effects observed during
treatment, and overall treatment cost. For inhaled therapy to be successful
against TB, affordable inhalers should be made available on a large scale in TBaffected nations. In the section below, we discuss the inhaler devices for drugs
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and vaccines separately since it requires different development and use
strategies.”
Devices for pulmonary drug delivery
“Lung deposition of ATDs to the affected areas is determined by the
aerodynamic particle size distribution, particle mass, and patients’ inspiratory
flow. Aerodynamic particle size distribution is optimized when the aerodynamic
diameter is between 1 and 3 um, a limitation that is easily overcome in the
formulation aspect of inhalable products. Similarly, particle mass is affected by
the added excipients, which can be optimized for deep lung delivery, for uptake
by alveolar macrophages, and to minimize mucociliary clearance. One major
limitation to the pulmonary route of administration, however, is the individual
variation observed among patients, such as inspiratory flow rate, tidal volume,
ability to hold breath after performing the inhalation maneuver, etc. Such
differences in patient-specific factors can be affected by many variables, such as
age and disease states (i.e., COPD), and these variations can potentially lead to
differences in clinical outcomes between patients despite using the same inhaler
device–ATDs combination. Historically, the aerosol devices used for pulmonary
delivery have been nebulizers, MDIs, and DPIs (see the section called “Devices
available”). One major limitation to using nebulizers is that these systems require
lengthy treatment time and waste much of the drug. Here, drug loss to the
environment is observed as the patient passively breathes, or the drug is
retained within the device; only an average of 10% of the drug is deposited into
the lung. In comparison, MDIs promise to provide more drug deposition;
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however, the effectiveness of this system is highly variable among patients. Drug
deposition is largely affected by the inspiratory flow rate, in which faster
inhalations may cause a significant amount of the drug to be deposited via
inertial impaction in conducting airways and oropharyngeal regions. Issues
regarding a patient’s ability to coordinate actuation of the device and inspiration
remains a frequent complication while using MDIs. Introduction of spacer and
valve holding chambers have helped minimize complications regarding hand-eye
coordination; this is achieved by slowing the aerosol velocity, which reduces drug
deposited at the oropharynx. However, the use of auxiliary attachments to MDIs
has previously led to compliance concerns during chronic use, especially in
pediatric patients. In contrast, DPIs are designed to decrease the coordination
difficulties associated with MDIs. This system relies on the patient’s inspiratory
flow rate, however, and can be negatively affected by humidity and changes in
temperature. Lung deposition from DPIs is further affected by the ability of the
drug to deaggregate from the carrier particles (i.e., lactose), or by the patient’s
inability to hold her or his breath after the inhalation maneuver, which may be
compromised in TB patients. Aerosol ATD formulations are further limited by the
excipients that are currently approved for pulmonary delivery. Pulmonary TB
therapeutics using novel but nonapproved excipients, such as biodegradable
polymers that are used to formulate nano- and microparticles, require additional
safety and toxicological data. In addition, many excipients that are generally
recognized as safe (GRAS) by other routes of administration are not approved
for pulmonary delivery because of the potential safety, toxicity, and pathological
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inflammation concerns. Interest in DPIs has arisen more recently due to the
delivery platform’s ability to generate high local drug concentration in the lungs,
as well as the improved stability of the powders compared to drug solutions. Dry
powder formulations encompass a few promising strategies for optimal
inhalational TB therapy, with liposomal, microparticle, and nanoparticle dry
powders at the forefront of this research. Liposomes encapsulating anti-TB drugs
can be utilized for pulmonary delivery as they are not immunogenic. Micro-and
nanoparticles formulated with polymeric excipients such as poly(l-lactic) acid and
poly(lactic-co-glycolic) acid may potentially have a positive impact on the
pharmacokinetic and pharmacodynamic parameters of ATDs. Such polymerbased formulations would allow for a less frequent dosing regimen by prolonging
the drug release profiles and leading to better patient compliance. Poly(l-lactic)
acid microparticles, for example, have displayed a slow in vitro release, where
only 70% the encapsulated ATDs was released in 10 days. Conversely, particles
delivered in the nanosized range are not suitable for inhalation purposes and
must be formulated into a larger, micron-size particles.”
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Appendix 2: Oral immunization with bacteriophage MS2-L2 VLPs protects
against oral and genital infection with multiple HPV types associated with
head & neck cancers and cervical cancer. Antiviral Research.

Lukai Zhai, Rashi Yadav, Nitesh K. Kunda, Dana Anderson, Elizabeth Bruckner,
Elliott K. Miller, Rupsa Basu, Pavan Muttil, Ebenezer Tumban

Contribution to this Publication:
Spray-freeze drying of VLPs into dry powder formulation
“Equal concentrations of MS2-31L2/16L2 VLPs and MS2-consL2(69-86)
VLPs were mixed together to obtain mixed MS2-L2 VLPs. Half of the mixed MS2L2 VLPs (100 µg) was further mixed with 2 µg each of the mucosal adjuvants,
cholera toxin (CT) and monophosphoryl lipid A (MPLA); control MS2 VLPs were
mixed with the same concentration of adjuvants. The mixed MS2-L2 VLPs and
MS2 VLPs, with or without mucosal adjuvants, were added to a 3% w/v MTDL
excipient solution (containing Mannitol (M, 75% w/w), Trehalose (T, 7.5% w/w),
Dextran (D, 2.5% w/w), and L-Leucine (L, 15% w/w). The VLPs were added at a
concentration of 8% w/w to the MTDL excipients and the VLPs-excipients were
then spray-freeze dried (SFD) in two steps. In the first step, the VLPs-excipients
suspensions were sprayed into a stainless-steel container filled partially with
liquid nitrogen. This was achieved by using a two-fluid nozzle (0.7 mm) which is
part of a Büchi B-290 mini spray-dryer; the spraying operating conditions were as
following: nitrogen flow (Q) between 10 and 15mm, and a VLPs excipients feed
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rate of ~ 4 mL/min. Subsequently, the liquid nitrogen in the steel container was
allowed to evaporate and the frozen droplets were transferred into a lyophilizer
(FreeZone® Triad™ Freeze Dry system, Model 74000 Series) [27] for
freezedrying (the second step). Freeze-drying was conducted under the following
conditions: pre-freeze for 3 h at -80 °C, primary drying at -10 °C for 24 h with a
ramp of 0.25 °C/min, followed by secondary drying at 15 °C for 4 8 h with a ramp
of 0.25 °C/min, and vacuum pressure of 1.51 mBar. All SFD products were
collected in glass scintillation vials and were stored under refrigeration until
further use.”
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Appendix 3: 2017 AFPE Gateway Award Fellowship Proposal. Efflux Pump
Inhibitors in PLGA Nanoparticles as an Adjunct to Isoniazid.

Student: Elliott Miller, Pharm.D. Candidate, Class of 2019
Mentor: Pavan Muttil, Ph.D. (Pharmaceutical Sciences), Nitesh Kunda, Ph.D.
(Post-Doctorate)

The World Health Organization’s 2015 report has identified tuberculosis
infections among the top ten causes of death worldwide (1). This disease can
remain dormant within the human body for years, and once active it requires
complex and extensive multidrug therapies administered over a course which
generally requires 6 to 9 months of intense drug regimens (2). This demanding
treatment has led to the emergence of drug-resistant Mycobacterium tuberculosis,
and now therapies require a different approach to combat the further selection and
advancement of these dangerous multidrug-resistant (MDR) and extreme drugresistant (XDR) (1). Identifying the mechanisms of resistance these organisms are
acquiring is absolutely crucial to further combat drug resistance and will continue
to allow first-line therapies to remain viable, extending the longevity of the few
antibiotics known to provide favorable outcomes in tuberculosis infections. It has
been observed by many researchers that M. tuberculosis is utilizing efflux pumps
to promote bacterial survival and is potentially mediating drug tolerance. (3, 4).
Researchers have successfully repurposed drugs such as verapamil (VER) and
thioridazine (TRZ) and have shown to these pharmaceuticals to be effective efflux

64

pump inhibitors (EPIs), combating novel drug tolerance mechanisms of
tuberculosis as well as potentiate the effects of first-line antibiotics such as rifampin
(RIF) and isoniazid (INH) (3,5). Various ways of incorporating these drugs into
formulation remains a struggle and determining the best route of administration,
release profile, optimized EPIs for each antibiotic, along with a plethora of other
characteristics remains an issue. One approach available for formulation is
encapsulating the administered drugs (antibiotic plus EPI) into nanoparticles (NPs)
made of biodegradable polymer such as poly(lactic-co-glycolic) acid (PLGA). This
formulation has the benefit of a sustained-release profile, targeting the
macrophages which M. tuberculosis reside, and greatly reducing TRZ toxicities in
vivo (5). Utilizing INH, being one of the drugs implemented in MDR and XDR, we
aim to develop an effective formulation incorporating either VER, TRZ or both EPIs
into this NP formulation. Each of these EPIs contributes a different mechanism of
efflux pump inhibition, as well as providing other novel mechanistic advantages to
combating drug resistance. (6,7). Further targeting can also be achieved by
creating an inhalational formulation, delivering the therapy directly to the affected
organ system. We hypothesize that a PLGA NP formulation incorporating
EPIs and INH into an inhalable delivery system will potentiate INH’s
antibacterial activity, allowing higher intra-bacterial concentrations of INH,
improving killing activity of INH as well as decreasing dosages by direct lung
administration, further optimizing tuberculosis treatment and combating
drug resistance.
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Aim 1: To optimize a NP incorporating EPI(s) and INH with outstanding
characteristics for inhalation, drug loading, as well as macrophage targeting.
Aim 2: To determine the effectiveness and proper dosing of the NP
formulation in vitro utilizing macrophage cell cultures.
Aim 3: To determine the utility of a novel anti-tuberculosis inhalational
formulation in vivo.

Aim 1: To optimize a NP incorporating EPI(s) and INH with outstanding
characteristics for inhalation, drug loading, as well as macrophage targeting.
Rationale: Nanoparticle formulations enhance targeting of macrophages, which is
the place of residence for many M. tuberculosis in an active tuberculosis infection.
Incorporating EPIs such as VER into this formulation will allow for greater antibiotic
concentrations to accumulate within the bacteria, enhancing killing and combating
one of the mechanisms tuberculosis utilizes for drug tolerance.

Methods: Formulate, spray dry, characterize

Aim 2: To determine the effectiveness and proper dosing of the NP
formulation in vitro utilizing macrophage cell cultures.

Rationale: Compare killing of our formulation versus free-drug (without NP) in vitro.
Determine dose, effectiveness, etc.
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Method: Infect macrophages, treat with various formulations, lyse macrophages
and:
1.) quantify CFUs
2.) measure amount of drug intra-bacterial

Aim 3: To determine the utility of a novel anti-tuberculosis inhalational
formulation in vivo.

Rationale: How well does this formulation perform in a live animal model? Are there
notable toxicities? Is there noticeable improvement in the outcomes of these
animals?

Method: Infect mice with TB. Treatment:
1.) NP alone
2.) NP-EPI
3.) NP-EPI-INH
4.) Free INH
5.) Free INH+ Free EPI
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